FTXH stock icon

First Trust Nasdaq Pharmaceuticals ETF
FTXH

$29.10
1.13%

Market Cap: 18.9M

0
Funds holding %
of 6,702 funds
–
Analysts bullish %
–
News positive %

Fund manager confidence

Based on 2024 Q1 SEC filings by fund managers ($100M+ AUM)

9% less capital invested

Capital invested by funds: $8.87M [Q4 2023] → $8.1M (-$769K) [Q1 2024]

8.94% less ownership

Funds ownership: 47.56% [Q4 2023] → 38.62% (-8.94%) [Q1 2024]

23% less funds holding

Funds holding: 22 [Q4 2023] → 17 (-5) [Q1 2024]

56% less first-time investments, than exits

New positions opened: 4 | Existing positions closed: 9

57% less repeat investments, than reductions

Existing positions increased: 3 | Existing positions reduced: 7

See Fund Rankings

Research analyst outlook

We haven’t received any recent analyst ratings for FTXH.

See Analyst Rankings

Financial journalist opinion

Positive
Zacks Investment Research
2 months ago
A Look at Pharma ETFs Post Q1 Earnings
Many industry bigwigs reported solid results, with some beating on earnings or revenues or both.
A Look at Pharma ETFs Post Q1 Earnings
Positive
Zacks Investment Research
3 months ago
JNJ Beats Q1 Earnings Estimates, Misses on Sales: ETFs in Focus
Johnson & Johnson (JNJ) continued with its long streak of earnings beat but lagged revenue estimates.
JNJ Beats Q1 Earnings Estimates, Misses on Sales: ETFs in Focus
Neutral
Zacks Investment Research
5 months ago
A Look at Pharma ETFs After Q4 Earnings
The fourth-quarter results of the healthcare sector have been unimpressive, with earnings of companies that have reported so far down 17.7% despite 7% revenue growth. However, many industry bigwigs reported solid results, with some beating on earnings or revenues or both.
A Look at Pharma ETFs After Q4 Earnings
See News Rankings